The DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice
Open accessAbstract
Influenza viruses are respiratory pathogens of public health concern worldwide with up to 650,000 deaths occurring each year. Seasonal influenza virus vaccines are employed to prevent disease, but with limited effectiveness. Development of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is necessary for reducing influenza virus prevalence. In this study, we have utilized lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccines to intradermally deliver a combination of conserved influenza virus antigens (hemagglutinin stalk, neuraminidase, matrix-2 ion channel, and nucleoprotein) and induce strong immune responses with substantial breadth and potency in a murine model. The immunity conferred by nucleoside-modified mRNA-lipid nanoparticle vaccines provided protection from challenge with pandemic H1N1 virus at 500 times the median lethal dose after administration of a single immunization, and the combination vaccine protected from morbidity at a dose of 50 ng per antigen. The broad protective potential of a single dose of combination vaccine was confirmed by challenge with a panel of group 1 influenza A viruses. These findings support the advancement of nucleoside-modified mRNA-lipid nanoparticle vaccines expressing multiple conserved antigens as universal influenza virus vaccine candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a single mRNA vaccine can encode multiple antigens, strengthening the immune response against resilient pathogens7”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [7]
In the citing paper
“Another study used LNPs to deliver a 50 ng dose of nucleoside-modified mRNA encoding three conserved influenza proteins: neuraminidase, nucleoprotein and matrix-2 ion channel protein (Fig. 4) in addition to the haemagglutinin stalk7. Incredibly, this minuscule mRNA dose generated broadly protective antibodies and protected mice from an extraordinarily large viral challenge (500× LD50).”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [7]
Citations
Cites
The EMBL-EBI search and sequence analysis tools APIs in 2019
Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationEfficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationHobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,003
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Self-citationHemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C., Kanekiyo, M., Kong, W., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 700
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 592
Self-citationA stable trimeric influenza hemagglutinin stem as a broadly protective immunogen
Impagliazzo, A., Milder, F. J., Kuipers, H., Wagner, M. V., Zhu, X., Hoffman, R. M. B., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J. W. A., et al. (2015) · Science · doi:10.1126/science.aac7263 · Cited by 591
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface
Lamb, R. A., Zebedee, S. L., & Richardson, C. D. (1985) · Cell · doi:10.1016/0092-8674(85)90211-9 · Cited by 581
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain
Steel, J., Lowen, A. C., Wang, T. T., Yondola, M. A., Gao, Q., Haye, K., García‐Sastre, A., & Palese, P. (2010) · mBio · doi:10.1128/mbio.00018-10 · Cited by 535
Self-citationPardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
Self-citationFeldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454 · cited 2×
“This low dose of vaccination is promising, as a major limitation to mRNA vaccines has been side effects associated with high doses of LNP, causing inflammation at the injection site.(57)”
BackgroundKrammer, F., Pica, N., Hai, R., Margine, I., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.00641-13 · Cited by 425
Self-citationChen, Y.-Q., Wohlbold, T. J., Zheng, N., Huang, M., Huang, Y., Neu, K. E., Lee, J., Wan, H., Rojas, K. T., Roubidoux, E. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.030 · Cited by 419
Self-citationChahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
Bakkouri, K. E., Descamps, F. J., Filette, M. D., Smet, A., Festjens, E., Birkett, A. J., van Rooijen, N., Verbeek, S. J., Fiers, W. C., & Saelens, X. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902147 · Cited by 335
M2e-based universal influenza A vaccine
Fiers, W. C., Filette, M. D., Bakkouri, K. E., Schepens, B., Roose, K., Schotsaert, M., Birkett, A. J., & Saelens, X. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.007 · Cited by 334
NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
Krammer, F., Fouchier, R. A. M., Eichelberger, M. C., Webby, R. J., Shaw‐Saliba, K., Wan, H., Wilson, P. C., Compans, R. W., Skountzou, I., & Monto, A. S. (2018) · mBio · doi:10.1128/mbio.02332-17 · Cited by 291
Self-citationProtection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
Epstein, S. L., Kong, W., Misplon, J. A., Lo, C.-Y., Tumpey, T. M., Xu, L., & Nabel, G. J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.047 · Cited by 285
Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281
Self-citationBroadly protective human antibodies that target the active site of influenza virus neuraminidase
Stadlbauer, D., Zhu, X., McMahon, M., Turner, J. S., Wohlbold, T. J., Schmitz, A. J., Strohmeier, S., Yu, W., Nachbagauer, R., Mudd, P. A., et al. (2019) · Science · doi:10.1126/science.aay0678 · Cited by 265
Self-citationUnmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257 · cited 1×
“Although most pre-clinical evaluations of mRNA-LNP vaccines have been performed in the murine model, studies in non-human primates and clinical trials in humans have supported the efficacy and translatability of this approach.(56,57) These studies show the ability of pre-clinical data to translate to effective vaccina…”
BackgroundSelf-citationDurbin, A. F., Wang, C., Marcotrigiano, J., & Gehrke, L. (2016) · mBio · doi:10.1128/mbio.00833-16 · Cited by 238
Wohlbold, T. J., Nachbagauer, R., Xu, H., Tan, G. S., Hirsh, A., Brokstad, K. A., Cox, R. J., Palese, P., & Krammer, F. (2015) · mBio · doi:10.1128/mbio.02556-14 · Cited by 235
Self-citationParhiz, H., Shuvaev, V. V., Pardi, N., Khoshnejad, M., Kiseleva, R. Y., Brenner, J. S., Uhler, T., Tuyishime, S., Mui, B. L., Tam, Y. K., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.015 · Cited by 233
Self-citationJohn, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.029 · Cited by 229
Modified mRNA Vaccines Protect against Zika Virus Infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.016 · Cited by 221
The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin
Thyagarajan, B., & Bloom, J. D. (2014) · eLife · doi:10.7554/elife.03300 · Cited by 202
Novel correlates of protection against pandemic H1N1 influenza A virus infection
Ng, S., Nachbagauer, R., Balmaseda, Á., Stadlbauer, D., Ojeda, S., PATEL, M. J., Rajabhathor, A., López, R., Guglia, A. F., Sánchez, N., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0463-x · Cited by 201
Self-citationAntrobus, R., Coughlan, L., Berthoud, T. K., Dicks, M. D. J., Hill, A. V. S., Lambe, T., & Gilbert, S. C. (2013) · Molecular Therapy · doi:10.1038/mt.2013.284 · Cited by 197
Self-citationEggink, D., Goff, P. H., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.02608-13 · Cited by 187
Self-citationMeyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., & Bukreyev, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix592 · Cited by 178
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins
Nachbagauer, R., Choi, A., Hirsh, A., Margine, I., Iida, S., Barrera, A., Marcela Ferrés, G., Albrecht, R. A., García‐Sastre, A., Bouvier, N. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3684 · Cited by 172
Self-citationMargine, I., Palese, P., & Krammer, F. (2013) · Journal of Visualized Experiments · doi:10.3791/51112 · Cited by 169
Self-citationM2e-Based Universal Influenza A Vaccines
Deng, L., Cho, K., Fiers, W. C., & Saelens, X. (2015) · Vaccines · doi:10.3390/vaccines3010105 · Cited by 168
Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154
Heaton, N. S., Leyva-Grado, V. H., Tan, G. S., Eggink, D., Hai, R., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.00969-13 · Cited by 147
Self-citationBernstein, D. I., Guptill, J. T., Naficy, A. B., Nachbagauer, R., Scorza, F. B., Feser, J., Wilson, P. C., Solórzano, A., der Wielen, M. V., Walter, E. B., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30393-7 · Cited by 140
Self-citationCoughlan, L., Sridhar, S., Payne, R., Edmans, M. D., Milicic, A., Venkatraman, N., Lugonja, B., Clifton, L., Qi, C., Folegatti, P. M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.02.011 · Cited by 138
Self-citationLindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132
Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J. B., Gregorio, E. D., Geall, A. J., Brazzoli, M., & Bertholet, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161193 · Cited by 127
Awasthi, S., Hook, L. M., Pardi, N., Wang, F., Myles, A., Cancro, M. P., Cohen, G. H., Weissman, D., & Friedman, H. M. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw7083 · Cited by 117
Self-citationNative Morphology of Influenza Virions
Noda, T. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00269 · Cited by 109
Structural Characterization of Viral Epitopes Recognized by Broadly Cross-Reactive Antibodies
Lee, P. S., & Wilson, I. A. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_413 · Cited by 95
Influenza A Virus Can Undergo Multiple Cycles of Replication without M2 Ion Channel Activity
Watanabe, T., Watanabe, S., Ito, H., Kida, H., & Kawaoka, Y. (2001) · Journal of Virology · doi:10.1128/jvi.75.12.5656-5662.2001 · Cited by 91
New Kids on the Block: RNA-Based Influenza Virus Vaccines
Scorza, F. B., & Pardi, N. (2018) · Vaccines · doi:10.3390/vaccines6020020 · Cited by 91
Self-citationEichelberger, M. C., Morens, D. M., & Taubenberger, J. K. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.025 · Cited by 91
Influenza Neuraminidase as a Vaccine Antigen
Eichelberger, M. C., & Wan, H. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_398 · Cited by 83
Cheng, Z.-J. J., Garvin, D., Paguio, A., Moravec, R. A., Engel, L., Fan, F., & Surowy, T. K. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.07.010 · Cited by 77
Lambe, T., Carey, J. B., Li, Y., Spencer, A. J., van Laarhoven, A., Mullarkey, C. E., Vrdoljak, A., Moore, A., & Gilbert, S. C. (2013) · Scientific Reports · doi:10.1038/srep01443 · Cited by 76
Jacobsen, H., Rajendran, M., Choi, A., Sjursen, H., Brokstad, K. A., Cox, R. J., Palese, P., Krammer, F., & Nachbagauer, R. (2017) · mBio · doi:10.1128/mbio.01463-17 · Cited by 73
Self-citationSchotsaert, M., Ysenbaert, T., Smet, A., Schepens, B., Vanderschaeghe, D., Stegalkina, S. S., Vogel, T. U., Callewaert, N., Fiers, W. C., & Saelens, X. (2016) · Scientific Reports · doi:10.1038/srep24402 · Cited by 56
Margine, I., Palese, P., & Krammer, F. (2013) · Journal of Visualized Experiments · doi:10.3791/51112-v · Cited by 54
Self-citationZhuang, Q., Wang, S., Liu, S., Hou, G., Li, J., Jiang, W., Wang, K., Peng, C., Liu, D., Guo, A., et al. (2019) · Virology Journal · doi:10.1186/s12985-019-1188-7 · Cited by 50
Choi, A., Bouzya, B., Franco, K.-D. C., Stadlbauer, D., Rajabhathor, A., Rouxel, R. N., Mainil, R., der Wielen, M. V., Palese, P., García‐Sastre, A., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900022 · Cited by 47
Self-citationFulton, B. O., Sun, W., Heaton, N. S., & Palese, P. (2018) · Journal of Virology · doi:10.1128/jvi.00754-18 · Cited by 27
Self-citationRekstin, A. R., Николаевна, И.-С. И., Petukhova, G. D., Korenkov, D. A., Losev, I., Smolonogina, T. A., Kotomina, T. S., Donina, S., Shcherbik, S., Bousse, T. L., et al. (2017) · BioMed Research International · doi:10.1155/2017/9359276 · Cited by 23
DiMenna, L. J., & Ertl, H. C. J. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-92165-3_15 · Cited by 22
Dhar, N., Kwatra, G., Nunes, M. C., Cutland, C., Izu, A., Nachbagauer, R., Krammer, F., & Madhi, S. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz927 · Cited by 14
Self-citationExtracellular truncated influenza virus nucleoprotein
Prokudina, E. N., Semenova, N. P., Chumakov, V. M., Rudneva, I. A., & Yamnikova, S. S. (2001) · Virus Research · doi:10.1016/s0168-1702(01)00264-7 · Cited by 5
Np, S., & Prokudina, E. N. (1991) · PubMed · Cited by 1
Flagged first, then by citations
2 of the 67 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Self-citationmRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775
Self-citationNdeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Metadata
- Authors
- Freyn, A. W., Ramos da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., de Souza Ferreira, L. C., Weissman, D., Krammer, F., Coughlan, L., Palese, P., Pardi, N., & Nachbagauer, R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- University of Pennsylvania (US)
- Acuitas Therapeutics (Canada) (CA)
- Corresponding author
- Pardi, Norbert
- Nachbagauer, Raffael
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 28
- Issue
- 7
- Pages
- 1569-1584
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC7335735
- OpenAlex
- W3016394521
- Cited by
- 299
- References
- 67
- Citations by year
- 2026: 25 · 2025: 58 · 2024: 50 · 2023: 55 · 2022: 58 · 2021: 44 · 2020: 9
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/01523-3)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI07647, 5P01AI097092-07, 75N93019C00051, R01-AI146101-01)
- U.S. Public Health Service (AI07647, 5P01AI097092-07)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- universal influenza vaccine, nucleoside-modified mRNA, lipid nanoparticle vaccine, multi-antigen vaccine, hemagglutinin stalk, neuraminidase, matrix protein 2, nucleocapsid protein, pandemic H1N1, immunological cross-reactivity, intradermal drug delivery
- MeSH terms
- mRNA Vaccines, Animals, Antibodies, Viral, Antigens, Viral, Disease Models, Animal, Influenza Vaccines, Injections, Intradermal, Liposomes, Neuraminidase, Nucleosides, Orthomyxoviridae Infections, Vaccines, Synthetic, Hemagglutinin Glycoproteins, Influenza Virus, Nucleocapsid Proteins, NIH 3T3 Cells, Mice, Influenza A Virus, H1N1 Subtype, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
